Syngene International's Q2 FY 2026-27 Quarterly Results

Result Summary

• Syngene International Ltd reported a 13.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 7.1%.
• Its expenses for the quarter were up by 5.2% QoQ and down 4.0% YoY.
• The net profit decreased 457.8% QoQ and decreased 52.0% YoY.
• The earnings per share (EPS) of Syngene International Ltd stood at 0.8 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Syngene International Ltd is a leading contract research and manufacturing organization (CRMO) that operates primarily in the pharmaceutical and biotechnology sectors. The company provides a range of research services across multiple platforms including small molecule chemistry, biologics, and custom synthesis. Syngene is known for its comprehensive suite of services that span discovery, development, and manufacturing, making it a critical partner for global pharmaceutical companies. As of the latest available data, Syngene continues to expand its capabilities and infrastructure to meet the growing demands of its clients. Recent developments include strategic partnerships and expansions in its research and development facilities to enhance service delivery. However, specific details about recent developments beyond the stated information are not available.

Revenue

In the second quarter of FY27, Syngene International Ltd reported a total income of ₹860.70 crores, marking a 13.1% increase quarter-over-quarter (QoQ) from ₹761.30 crores in Q1FY27. However, compared to the same quarter in the previous fiscal year (Q2FY26), there was a 7.1% decline year-over-year (YoY) from ₹926.00 crores. This demonstrates a substantial recovery from the previous quarter's performance but also indicates a reduction when compared to the previous year's performance for the same quarter. The quarterly growth indicates a positive adjustment in revenue streams, although the annual comparison reflects the challenges faced in maintaining year-over-year revenue growth.

Profitability

The profitability of Syngene International Ltd in Q2FY27 shows a marked improvement on a quarterly basis, with a profit before tax (PBT) of ₹47.00 crores compared to a loss of ₹19.20 crores in Q1FY27, representing a dramatic QoQ improvement of 344.8%. However, when compared to Q2FY26, where the PBT was ₹85.20 crores, there is a decline of 44.8% YoY. The profit after tax (PAT) also reflects a similar trend, with the company reporting a PAT of ₹32.20 crores in Q2FY27, recovering from a loss of ₹9.00 crores in Q1FY27, a QoQ change of 457.8%. This is, however, a 52.0% decrease from the ₹67.10 crores achieved in Q2FY26. Earnings per share (EPS) improved to ₹0.80 in Q2FY27 from a negative ₹0.22 in the previous quarter, yet it decreased by 52.1% from ₹1.67 in the same quarter of the previous year.

Operating Metrics

Total expenses for Syngene International Ltd in Q2FY27 were recorded at ₹807.00 crores, reflecting a 5.2% increase from ₹767.00 crores in Q1FY27. When compared to Q2FY26, there is a 4.0% decrease from ₹840.80 crores. The tax expense for the quarter was ₹14.80 crores, which marks a substantial change from a negative tax position of ₹10.20 crores in Q1FY27 and a decrease of 18.2% from ₹18.10 crores in Q2FY26. These figures indicate substantial changes in the company's cost structures and tax liabilities over the quarters and year-over-year. While the company has managed to reduce its total expenses YoY, the QoQ increase in expenses reflects operational adjustments in response to revenue changes. The tax expense variations also showcase the dynamic fiscal environment within which Syngene operates.